Abstract
Objective: To review the literature relating to the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia (PDD).
Method: MEDLINE (1966 – December 2004), PsychINFO (1972 – December 2004), EMBASE (1980 – December 2004), CINHAL (1982 – December 2004), and the Cochrane Collaboration were searched in December 2004.
Results: Three controlled trials and seven open studies were identified. Efficacy was assessed in three key domains: cognitive, neuropsychiatric and parkinsonian symptoms.
Conclusion: Cholinesterase inhibitors have a moderate effect against cognitive symptoms. There is no clear evidence of a noticeable clinical effect against neuropsychiatric symptoms. Tolerability including exacerbation of motor symptoms – in particular tremor – may limit the utility of cholinesterase inhibitors.
Method: MEDLINE (1966 – December 2004), PsychINFO (1972 – December 2004), EMBASE (1980 – December 2004), CINHAL (1982 – December 2004), and the Cochrane Collaboration were searched in December 2004.
Results: Three controlled trials and seven open studies were identified. Efficacy was assessed in three key domains: cognitive, neuropsychiatric and parkinsonian symptoms.
Conclusion: Cholinesterase inhibitors have a moderate effect against cognitive symptoms. There is no clear evidence of a noticeable clinical effect against neuropsychiatric symptoms. Tolerability including exacerbation of motor symptoms – in particular tremor – may limit the utility of cholinesterase inhibitors.
| Original language | English |
|---|---|
| Pages (from-to) | 403-409 |
| Number of pages | 7 |
| Journal | Acta Psychiatrica Scandinavica |
| Volume | 111 |
| Issue number | 6 |
| Early online date | 25 Mar 2005 |
| DOIs | |
| Publication status | Published - 29 Mar 2005 |
Keywords
- aged
- aged 80 and over
- cholinesterase inhibitors
- dementia
- humans
- middle aged
- Parkinson disease
- randomized controlled trials as topic
Fingerprint
Dive into the research topics of 'A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver